First, a substantial proportion of patients included in the CALGB 40601 and PAMELA trials received trastuzumab combined with lapatinib, a dual treatment used in the metastatic setting but not approved for early-stage ERBB2/HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast cancer.